Welcome to ACCESS DMD, the Marathon Expanded Access Program
Thank you for your interest in ACCESS DMD. MP-104-CL-037 is an open label, expanded access protocol intended to provide treatment with MP-104 (deflazacort) to children, adolescents, and/or adults with Duchenne muscular dystrophy, in the United States. ACCESS DMD is sponsored by Marathon Pharmaceuticals, LLC. The program will be completed according to the guidelines of Good Clinical Practice.